SYNERGISTIC ACTIVITY OF CURCUMIN WITH CIPROFLOXACIN AND TETRACYCLINE: A COMPARATIVE REVIEW TO COMBAT ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) is a mounting global health challenge that is steadily undermining the power of frontline antibiotics. Ciprofloxacin and tetracycline, once dependable for a wide range of infections, are now losing effectiveness due to widespread misuse and the rapid spread of resistance. To extend the lifespan of these agents, new approaches are needed. One emerging strategy is the use of natural adjuvants that can restore or enhance antibiotic activity. Curcumin, the principal compound of Curcuma longa, has drawn attention as a promising candidate because of its safety record and wide range of biological actions. Curcumin acts on bacteria through several pathways. It can block efflux pumps, destabilize cell membranes, generate reactive oxygen species, and disrupt biofilm structures. When paired with ciprofloxacin, Curcumin strengthens activity against Gram-negative organisms by improving drug penetration and amplifying DNA damage. In combination with tetracycline, its effects appear stronger against Gram-positive bacteria, particularly biofilm-associated pathogens such as MRSA, where it enhances ribosomal inhibition. Although both combinations have shown promise, they act in different ways, and no study has yet compared them directly. The major obstacle remains Curcumin’s poor solubility and rapid metabolism, which limit its availability in the body. Innovative delivery systems—such as nanoparticles, micelles, liposomes, piperine co-administration, and topical preparations—are being explored to overcome these barriers. Still, most evidence comes from in vitro experiments, with only a few animal studies and no clinical trials to date. This review brings together current findings on Curcumin’s synergy with ciprofloxacin and tetracycline, highlights the lack of direct comparisons, and examines how formulation strategies may support clinical translation. It concludes by outlining future directions and emphasizes Curcumin’s potential as a safe, cost-effective adjuvant in the fight against AMR.